Forward BIOLABS, in partnership with BioForward Madison, announced today the first round of awardees of the Innovation to Commercialization Pipeline (ICP) program.

The awardees from the Madison area include Immuto Scientific, Phoenix-Aid and Stem Pharm.

“We’re excited to officially announce these ICP awardees and begin working with this outstanding group of companies,” Forward BIOLABS CEO and Co-Founder Jessica Martin Eckerly said in a statement. “This first round of awards marks an important milestone for the program as we provide financial support to overcome commercialization risks and strengthen their investment readiness. ICP is one more way Forward BIOLABS is advancing its mission to support early-stage startups at critical points in their growth.”

According to a release, the 18 awardees span a broad range of Wisconsin’s biohealth sectors, including biomanufacturing, medical devices and pharmaceuticals, among others.